Assembly Biosciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Assembly Biosciences reports positive clinical data for multiple programs and Gilead exercises its option to license the HPI program for recurrent genital herpes, significantly boosting revenue and liquidity.
NASDAQ
10-K: Assembly Biosciences Reports Progress in Viral Disease Therapeutics Development in 2024 10-K Filing
Assembly Biosciences highlights advancements in its pipeline of viral disease therapeutics, including recurrent genital herpes, hepatitis delta virus, and hepatitis B virus, in its 2024 10-K filing.
NASDAQ
Assembly Biosciences' 10-K filing details the company's capital structure, stock information, and regulatory environment, highlighting its focus on developing therapeutics for viral diseases.